[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
Read more 
Probes of interest in oncology, immunology, central nervous system diseases and rare diseases
Our chemical biology-based drug discovery approach has generated a set of potent and high selective probes with promising drug-like properties that are attractive starting points for new projects. Many of these compounds are active at the sub-nanomolar level and demonstrate exceptional initial selectivity on kinases of major interest. Today, Oncodesign does not have internal capacity to capitalize on all available probes.
Oncodesign is committed to promoting partnerships in these early stages of drug discovery. We are looking for partners with complementary skills to develop the therapeutic potential of these small macrocyclic molecules more quickly. We share early probes under a simple MTA to allow rapid validation in our partners’ models.
Our probes in development
